Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2023-04-25 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：公司章程（2023年修订）
Governance Information Classification · 95% confidence The document is titled "上海美迪西生物医药股份有限公司章程" which translates to "Articles of Association of Shanghai Medicilon Inc." It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, shareholder meetings, and governance rules. The content is a comprehensive set of corporate bylaws or articles of association, which govern the internal rules and governance practices of the company. There is no indication that this is an annual report, earnings release, or any financial statement. It is not a notice or announcement but a full governance document. Therefore, the document fits best under the category of Governance Information (CGR). The document length (15,000 characters) and detailed content support this classification with high confidence.
2023-04-25 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司2022年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a securities company (广发证券股份有限公司) regarding the 2022 annual verification of the deposit and use of raised funds by Shanghai Medicilon Inc. It includes specific financial figures about the amount raised, usage, balances, and compliance with regulatory requirements. It references regulatory guidelines and includes detailed tables of fund usage and management. The document is lengthy (7,989 characters) and contains substantive financial data and analysis about the use of raised funds for the fiscal year 2022. This matches the characteristics of an Audit Report / Information (AR) as it focuses on the audit and verification of the use of raised funds, compliance with regulations, and includes audit opinions from the sponsor institution. It is not an announcement or a brief summary, nor is it a full annual report or earnings release. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2022
2023-04-25 Chinese
美迪西：关于2022年度利润分配预案及资本公积转增股本方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from Shanghai Medicilon Inc. regarding the 2022 annual profit distribution plan and capital reserve to share capital conversion plan. It details the proposed cash dividend per share, the capital reserve conversion ratio, the total amounts involved, and the rationale behind the dividend payout ratio being below 30%. It also includes the approval status from the board of directors, independent directors, and supervisory board, and states that the plan will be submitted to the 2022 annual general meeting for approval. The document is primarily about the company's dividend distribution and capital increase plan, which fits the category of Notice of Dividend Amount (DIV). The document length is 3495 characters, which is relatively short but contains substantive information about dividend distribution, not just an announcement of a report publication. Therefore, it is not a Report Publication Announcement (RPA). It is not a full annual report or earnings release but a specific announcement about dividends and capital changes related to equity distribution. Hence, the best classification is DIV (Notice of Dividend Amount).
2023-04-25 Chinese
美迪西：独立董事工作制度（2023年修订）
Governance Information Classification · 95% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System'. It details the rules, responsibilities, nomination, election, rights, and duties of independent directors within the company. It references company governance, legal compliance, and internal board structure. There is no financial data, earnings information, or report publication mentioned. The content is focused on governance practices and internal rules regarding independent directors. Therefore, this document fits the category of Governance Information (CGR). The document length is sufficient and it is not a brief announcement or certification, so it is not RPA or RNS. Hence, the classification is CGR with high confidence.
2023-04-25 Chinese
美迪西：董事会议事规则（2023年修订）
Governance Information Classification · 100% confidence The document is titled "董事会议事规则" which translates to "Rules of Procedure for the Board of Directors" of Shanghai Medicilon Inc. It details the composition, powers, meeting procedures, voting rules, and responsibilities of the board of directors. It is a governance document outlining internal rules and structure of the board rather than a financial report, announcement, or meeting material. There is no indication of financial data, audit results, voting results, or any other report type. The content fits the description of Governance Information (CGR) which covers internal rules, board structure, and governance practices.
2023-04-25 Chinese
美迪西：监事会关于终止实施2021年限制性股票激励计划的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal opinion from the Supervisory Board regarding the termination of the 2021 restricted stock incentive plan. It references relevant laws and regulations and concludes with the board's agreement to terminate the plan. There is no financial data, no report publication, no voting results, no management changes, and no earnings or capital updates. The document is a regulatory compliance statement related to corporate governance and stock incentive plans, fitting best under Regulatory Filings (RNS) as it does not fit other specific categories.
2023-04-25 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.